Bausch + Lomb has bought the assets and U.S. rights...

Bausch + Lomb has bought the assets and U.S. rights for Zirgan from Sirion Therapeutics. Zirgan is a topical anti-viral used to treat acute herpetic keratitis, or corneal ulcers, a condition that often results in corneal transplants. It is caused by the herpes simplex virus, and recurs repeatedly, leading to ...

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.


Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

Or sign-up for a trial month for just 9,90€. To continue reading this article register now.